Antimicrobial Agents Practice Questions

Q: What is the drug of choice in a patient with severe complicated falciparum malaria?

Artesunate. **Explanation:** **Artesunate** is the current **Drug of Choice (DOC)** for severe or complicated *Plasmodium falciparum* malaria, as recommended by both the WHO and National Guidelines. 1. **Why Artesunate is correct:** Intravenous (IV) Artesunate is a water-soluble artemisinin derivative that acts rapidly against all erythrocytic stages of the parasite (including young rings). It clears parasitemia faster than quinine and significantly reduces mortality rates in both adults (SEAQUAMAT trial) and children (AQUAMAT trial). It also has a superior safety profile with a lower risk of hypoglycemia. 2. **Why other options are incorrect:** * **Chloroquine:** While it was once the mainstay, widespread resistance in *P. falciparum* makes it ineffective for severe cases. It is now primarily used for *P. vivax* (where sensitive). * **Quinine:** Previously the DOC, it is now considered a second-line alternative. It requires slow IV infusion, carries a high risk of **cinchonism**, and frequently causes refractory hypoglycemia due to hyperinsulinemia. * **Artemether:** This is a lipid-soluble derivative usually administered intramuscularly. Its absorption is erratic compared to the rapid bioavailability of IV Artesunate, making it less ideal for emergency stabilization. **High-Yield Clinical Pearls for NEET-PG:** * **Dosing Schedule:** IV Artesunate is given at 0, 12, and 24 hours, then once daily. * **Transition:** Once the patient can tolerate oral medication, a full 3-day course of **ACT (Artemisinin-based Combination Therapy)** must be completed. * **Side Effect:** Watch for **Post-Artesunate Delayed Hemolysis (PADH)**, which can occur 1–3 weeks after treatment. * **Pregnancy:** IV Artesunate is safe and recommended for severe malaria in **all trimesters** of pregnancy.

Q: Beta-lactam ring is present in all of the following except?

Vancomycin. **Explanation:** The core concept tested here is the structural classification of cell wall synthesis inhibitors. **Beta-lactam antibiotics** are defined by the presence of a four-membered beta-lactam ring, which is essential for their antibacterial activity as it mimics the D-Ala-D-Ala substrate of penicillin-binding proteins (PBPs). **Why Vancomycin is the correct answer:** Vancomycin is a **Glycopeptide** antibiotic, not a beta-lactam. While it also inhibits cell wall synthesis, its mechanism is distinct: it binds directly to the **D-Ala-D-Ala terminus** of the nascent peptidoglycan pentapeptide, sterically hindering polymerization (transglycosylation). It lacks the beta-lactam ring structure entirely. **Analysis of Incorrect Options:** * **Sulbactam:** This is a **Beta-lactamase inhibitor**. Although it has weak intrinsic antibacterial activity, it possesses a beta-lactam ring that allows it to act as a "suicide inhibitor" by binding irreversibly to beta-lactamase enzymes. * **Imipenem:** This belongs to the **Carbapenem** class. Carbapenems are characterized by a beta-lactam ring fused to a five-membered ring system with a carbon at position 1. * **Cephalexin:** This is a **First-generation Cephalosporin**. All cephalosporins contain a beta-lactam ring fused to a six-membered dihydrothiazine ring. **High-Yield Clinical Pearls for NEET-PG:** 1. **Beta-lactam families:** Penicillins, Cephalosporins, Monobactams (e.g., Aztreonam), Carbapenems, and Beta-lactamase inhibitors (Clavulanic acid, Sulbactam, Tazobactam). 2. **Vancomycin "Red Man Syndrome":** An infusion-related reaction caused by direct histamine release (not a true IgE-mediated allergy). 3. **Mechanism of Resistance:** The most common resistance to Vancomycin (VRSA/VRE) involves the alteration of the binding site from **D-Ala-D-Ala to D-Ala-D-Lac**.

Q: Which of the following antitubercular drug combinations is preferred in severe liver disease?

Streptomycin + Ethambutol. **Explanation:** The management of tuberculosis in patients with severe liver disease requires avoiding **hepatotoxic** drugs to prevent further hepatic injury. **1. Why Streptomycin + Ethambutol is correct:** Among the first-line anti-tubercular drugs (HRZES), **Streptomycin (S)** and **Ethambutol (E)** are the only two drugs that are **not hepatotoxic**. * **Streptomycin** is an aminoglycoside excreted primarily by the kidneys. * **Ethambutol** is an antimetabolite also primarily excreted via renal mechanisms. In cases of severe liver dysfunction (e.g., cirrhosis or acute hepatitis), the standard hepatotoxic regimen (Isoniazid, Rifampicin, and Pyrazinamide) is contraindicated. A combination of S + E (often supplemented with a fluoroquinolone) is the safest alternative. **2. Why other options are incorrect:** * **Isoniazid (H):** Highly hepatotoxic; it causes hepatitis through its metabolite, acetylhydrazine. * **Rifampicin (R):** Hepatotoxic; it causes cholestatic jaundice and induces microsomal enzymes. * **Pyrazinamide (Z):** The **most hepatotoxic** of all first-line drugs. Options A, C, and D are incorrect because they all contain at least one hepatotoxic agent (H or R), which could precipitate liver failure in a patient with pre-existing severe liver disease. **Clinical Pearls for NEET-PG:** * **Order of Hepatotoxicity:** Pyrazinamide > Isoniazid > Rifampicin. * **Safe in Liver Disease:** Streptomycin, Ethambutol, and Fluoroquinolones (like Levofloxacin). * **Safe in Renal Failure:** Rifampicin and Isoniazid (as they are metabolized by the liver). Ethambutol and Streptomycin require dose adjustment or avoidance in renal failure. * **Visual Side Effect:** Ethambutol causes optic neuritis (check visual acuity/color vision). * **Ototoxicity:** Streptomycin causes vestibulocochlear nerve damage.

Q: A patient suffering from AIDS is on Zidovudine, Lamivudine, and Indinavir therapy. He develops pulmonary tuberculosis for which treatment is started. Which of the following antitubercular drugs should be avoided in him?

Rifampicin. ### Explanation The correct answer is **Rifampicin (Option D)**. **1. Why Rifampicin is avoided:** The patient is on a HAART (Highly Active Antiretroviral Therapy) regimen containing **Indinavir**, which is a **Protease Inhibitor (PI)**. Rifampicin is a potent **microsomal enzyme inducer** (specifically Cytochrome P450 3A4). It significantly increases the metabolism of Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), leading to sub-therapeutic plasma levels of these drugs [1]. This can result in treatment failure and the development of drug-resistant HIV strains. **2. Why other options are incorrect:** * **Isoniazid (INH), Ethambutol, and Pyrazinamide:** These drugs do not have significant induction or inhibition effects on the CYP450 enzyme system. They do not interfere with the pharmacokinetics of Indinavir, Zidovudine, or Lamivudine and are considered safe to use in standard doses in HIV-TB co-infection [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rifabutin vs. Rifampicin:** In patients on Protease Inhibitors, **Rifabutin** is the preferred substitute for Rifampicin [1]. It is a much weaker enzyme inducer and has less impact on PI levels [2]. * **Integrase Inhibitors:** If a patient is on **Dolutegravir**, the dose must be doubled (50mg BD instead of OD) if Rifampicin is co-administered. * **Indinavir Side Effect:** Remember that Indinavir is notorious for causing **nephrolithiasis** (kidney stones) and crystalluria; patients must stay well-hydrated. * **Zidovudine Side Effect:** Monitor for **anemia/neutropenia**, as it causes bone marrow suppression. * **Lamivudine:** It is the safest NRTI and is also active against the Hepatitis B virus (HBV).

Q: Combination chemotherapy is used in tuberculosis in order to reduce which of the following?

Development of drug resistance. **Explanation:** The primary rationale for using combination chemotherapy in Tuberculosis (TB) is to **prevent the development of drug resistance**. *Mycobacterium tuberculosis* undergoes spontaneous chromosomal mutations at a predictable frequency (e.g., 1 in $10^6$ bacilli for Isoniazid and 1 in $10^8$ for Rifampicin). In a typical cavitary TB lesion containing $10^9$ to $10^{12}$ bacilli, monotherapy would inevitably select for resistant mutants, leading to treatment failure. By using multiple drugs with different mechanisms of action simultaneously, the probability of a bacterium developing resistance to all drugs at once becomes mathematically negligible (e.g., $10^{-6} \times 10^{-8} = 10^{-14}$). **Analysis of Incorrect Options:** * **A. Side effects of drugs:** Combination therapy often *increases* the risk of adverse effects (e.g., additive hepatotoxicity of Isoniazid, Rifampicin, and Pyrazinamide). * **B. Cost of therapy:** Using multiple drugs is generally more expensive than using a single agent. * **C. Dosage of drugs:** In TB, drugs are used at their full therapeutic doses; combination therapy does not allow for dose reduction of individual components. **High-Yield Clinical Pearls for NEET-PG:** * **DOTS (Directly Observed Treatment Short-course):** The standard strategy to ensure compliance and prevent resistance. * **Bactericidal vs. Bacteriostatic:** Isoniazid, Rifampicin, Pyrazinamide, and Streptomycin are bactericidal; Ethambutol is primarily bacteriostatic. * **Sterilizing Effect:** Rifampicin and Pyrazinamide are the most effective at killing persistent/dormant bacilli, which helps in preventing relapse and shortening the duration of therapy. * **MDR-TB:** Defined as resistance to at least **Isoniazid and Rifampicin**.

Q: What is the primary treatment for Herpes zoster?

Valacyclovir. **Explanation:** **Primary Concept:** Herpes zoster (shingles) is caused by the reactivation of the **Varicella-Zoster Virus (VZV)**. The mainstay of treatment is antiviral therapy using nucleoside analogs that inhibit viral DNA polymerase. **Valacyclovir** is the preferred oral treatment because it is a prodrug of acyclovir with significantly higher oral bioavailability (3–5 times higher), leading to better plasma concentrations and a more convenient dosing schedule (TID vs. 5 times daily for acyclovir). It accelerates the healing of lesions and reduces the duration of post-herpetic neuralgia. **Analysis of Options:** * **A. Zidovudine (AZT):** A Nucleoside Reverse Transcriptase Inhibitor (NRTI) used primarily in the treatment of **HIV/AIDS**. It has no activity against DNA viruses like VZV. * **C. Ribavirin:** A broad-spectrum antiviral used mainly for **Hepatitis C** (in combination with interferon) and **RSV** (Respiratory Syncytial Virus). It is not effective for Herpes viruses. * **D. Nevirapine:** A Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) used exclusively for **HIV-1** infection and prevention of mother-to-child transmission. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Valacyclovir/Acyclovir requires initial phosphorylation by **viral Thymidine Kinase** to become active (Acyclovir monophosphate). This ensures selective toxicity. * **Timing:** Treatment should ideally be initiated within **72 hours** of rash onset to be most effective. * **Drug of Choice for CMV:** Ganciclovir (not acyclovir). * **Foscarnet:** Used for acyclovir-resistant Herpes or CMV; it does *not* require viral thymidine kinase for activation.

Q: Which is the most effective antitubercular drug against slow multiplying intracellular mycobacteria?

Rifampicin. The effectiveness of antitubercular drugs (ATT) depends on their ability to target specific subpopulations of *Mycobacterium tuberculosis* based on their metabolic activity and location. **1. Why Rifampicin is correct:** Mycobacteria exist in four distinct populations. **Rifampicin** is unique because it is highly effective against **slowly multiplying organisms** (spurters) that reside within caseous material or intracellularly [1], [2]. It inhibits bacterial DNA-dependent RNA polymerase, exerting a potent bactericidal effect even during brief periods of metabolic activity [2]. This makes it the most important drug for preventing relapses (sterilizing action). **2. Why the other options are incorrect:** * **Isoniazid (INH):** While it is the most potent bactericidal drug, it is primarily effective against **rapidly multiplying** extracellular bacilli. It has minimal effect on slow growers. * **Pyrazinamide:** This drug is specifically active against bacilli in an **acidic medium** (intracellularly within macrophages). While it targets a specific niche, Rifampicin is considered more broadly effective against the "slowly multiplying" population across different environments. * **Ethambutol:** This is a **bacteriostatic** drug that inhibits cell wall synthesis. It is the least potent of the first-line drugs [3] and does not have significant sterilizing activity against slow growers. **High-Yield NEET-PG Pearls:** * **Best Sterilizing Action:** Rifampicin > Pyrazinamide. * **Early Bactericidal Activity (EBA):** Isoniazid (highest in the first 48 hours). * **Site of Action:** Pyrazinamide works best at acidic pH; Streptomycin works only at alkaline pH (extracellular). * **Mnemonic for Populations:** * **I**NH = **I**nside cavities (Rapidly growing). * **R**ifampicin = **R**esting/Slowly growing. * **P**yrazinamide = **P**hago-lysosomes (Acidic pH).

Q: Which of the following is a protease inhibitor?

Saquinavir. **Explanation:** The question tests the classification of Antiretroviral Therapy (ART) drugs used in the management of HIV. **Correct Option: B. Saquinavir** Saquinavir belongs to the **Protease Inhibitors (PIs)** class [5]. These drugs work by inhibiting the viral enzyme **HIV-1 protease** [4], which is responsible for cleaving precursor polyproteins (Gag-Pol) into functional mature proteins [1]. Inhibition of this enzyme results in the production of immature, non-infectious virions. * **High-Yield Tip:** All Protease Inhibitors typically end with the suffix **"-navir"** (e.g., Ritonavir, Atazanavir, Darunavir) [3]. **Incorrect Options:** * **A. Lamivudine (3TC):** This is a **Nucleoside Reverse Transcriptase Inhibitor (NRTI)**. It is a cytosine analog used in both HIV and Hepatitis B treatment. * **C. Delavirdine:** This is a **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)** [2]. Unlike NRTIs, NNRTIs bind directly to the reverse transcriptase enzyme at a site different from the active site (allosteric inhibition). * **D. Zidovudine (AZT):** This is the prototype **NRTI** (thymidine analog). It is historically significant as the first drug approved for HIV and is notably used to prevent mother-to-child transmission. **Clinical Pearls for NEET-PG:** 1. **Metabolic Side Effects:** Protease Inhibitors are frequently associated with **lipodystrophy** (buffalo hump), hyperglycemia (insulin resistance), and hyperlipidemia. 2. **Ritonavir Boosting:** Ritonavir is a potent **CYP3A4 inhibitor** [5]. It is often used in low doses not for its antiviral effect, but to "boost" the plasma concentrations of other PIs. 3. **Indinavir:** A specific PI known for causing **nephrolithiasis** (crystalluria).

Question 1

AZT, ddI, and HAART are combinations of three drugs used in AIDS. What is their primary mechanism of action?

Accepted Answer

Nucleoside reverse transcriptase inhibitors

Answer

Inhibitory effects on viral DNA

Answer

Inhibit the synthesis of group 24

Answer

P53 anti-apoptotic molecule synthesis

Question 2

What is the drug of choice in a patient with severe complicated falciparum malaria?

Accepted Answer

Artesunate

Answer

Chloroquine

Answer

Quinine

Answer

Artemether

Question 3

Beta-lactam ring is present in all of the following except?

Accepted Answer

Vancomycin

Answer

Sulbactam

Answer

Imipenem

Answer

Cephalexin

Question 4

Which of the following antitubercular drug combinations is preferred in severe liver disease?

Accepted Answer

Streptomycin + Ethambutol

Answer

Streptomycin + Isoniazid

Answer

Isoniazid + Rifampicin

Answer

Rifampicin + Ethambutol

Question 5

A patient suffering from AIDS is on Zidovudine, Lamivudine, and Indinavir therapy. He develops pulmonary tuberculosis for which treatment is started. Which of the following antitubercular drugs should be avoided in him?

Accepted Answer

Rifampicin

Answer

Isoniazid (INH)

Answer

Ethambutol

Answer

Pyrazinamide

Question 6

Combination chemotherapy is used in tuberculosis in order to reduce which of the following?

Accepted Answer

Development of drug resistance

Answer

Side effects of drugs

Answer

Cost of therapy

Answer

Dosage of drugs

Question 7

What is the primary treatment for Herpes zoster?

Accepted Answer

Valacyclovir

Answer

Zidovudine

Answer

Ribavirin

Answer

Nevirapine

Question 8

Which is the most effective antitubercular drug against slow multiplying intracellular mycobacteria?

Accepted Answer

Rifampicin

Answer

Isoniazid

Answer

Pyrazinamide

Answer

Ethambutol

Question 9

Which of the following is a protease inhibitor?

Accepted Answer

Saquinavir

Answer

Lamivudine

Answer

Delavirdine

Answer

Zidovudine

Question 10

Which of the following is a true statement regarding Rifampicin?

Accepted Answer

Increased metabolism of cyclosporine when given concomitantly

Answer

Acts by inhibiting mycolic acid synthesis

Answer

Dose adjustment is needed in renal failure

Answer

Gets concentrated intracellularly mainly in neutrophils

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?